Pharmaceutical Industry Reports Venous Thromboembolism (VTE) Market | Page 2

REPORT DESCRIPTION
Venous Thromboembolism (VTE) Market – Overview
According to the International Society on Thrombosis and Hemostasis, Inc., venous thromboembolism (VTE) is a
leading cause of death and disability worldwide. Approximately 10 million cases of venous thromboembolism
occur annually. VTE refers to the formation of blood clots in vein. If the clot is in deep vein (usually leg), it is
called as deep vein thrombosis, while a clot in lungs is termed as pulmonary embolism.
There are around 100,000 to 300,000 VTE related deaths reported annually in the U.S. (International Society on
Thrombosis and Hemostasis, Inc.). The number is much higher in Europe, which is at 544,000 deaths annually.
Moreover, it is also estimated that up to 60% of VTE cases occur during or after hospitalization. This preventable
health condition is usually overlooked as a major public health problem leading to deaths.
Heparin has been the gold standard for treating VTE. In a recent study published (2017) in the New England
Journal of Medicine, Rivaroxaban has shown to be more effective in reducing the risk of recurrent events in
patients with venous thromboembolism in equipoise with continued anticoagulation medications compared to
Aspirin. Devices used for treating VTE include compression stockings, and intermittent pneumatic compression
devices. Thrombolytic therapy includes administering tissue plasminogen activator.